Standard BioTools 株価情報 (NASDAQ: LAB)

Standard BioTools (NASDAQ:LAB) 株価情報

Standard BioTools

Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

CYAN

バタフライ・ネットワークおよびその他2つの5ドル未満の株ダウ平均株価指数は金曜日に50ドル以上上昇して取引を終えた。内部者が株を売買した場合、それは同社の見通しに対する彼らの信頼または懸念を示唆する。ペニー株に興味を持つ投資家やトレーダーは、この要素を総合的な投資や取引の意思決定の一因と考えることができよう。

ダウ平均株価指数は50ドルの上昇を記録　上昇の要因は？

Standard BioTools Inc

Direxion Daily S&P Biotech Bear 3X Shares

LABORATORIOS FARMACEUTICO by LABORATORIOS FARMACEUTICOS ROVI SA

Laboratorios Farmaceuticos Rovi SA

Landos Biopharma Inc COM NEW

LABS Group

Direxion Daily S&P Biotech Bull 3X Shares

METASPHERE LABS INC by METASPHERE LABS INC.

Metasphere Labs Inc

Economist Lyn Alden warns that U.S. fiscal deficits are an unstoppable force, driving demand <a href="https://www.benzinga.com/25/05/45610847/bitcoins-setup-exact-same-like-golds-explosion-during-1970s-says-analyst-but-critics-have-something-to-add">for scarce assets</a> like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and gold.
What Happened: Speaking at Bitcoin conference 2025 last week, Alden popularized the phrase &#8220;nothing stops this train&#8221;—borrowed from the show Breaking Bad—to describe a fiscal trajectory that, in her view, is now governed by both mathematical inevitability and political intransigence.
"We're in a system where the brakes are gone," she <a href="https://www.youtube.com/watch?v=Giuzcd4oxIk">said</a>. "Raising interest rates only accelerates the federal deficit faster than it slows private borrowing."
Using historical data, Alden demonstrated how federal deficits used to rise during recessions and shrink during recoveries. 
That relationship broke down after 2017. Since then, unemployment has remained low while deficits have ballooned, reaching 6–7% of GDP outside of crisis periods.
"This is not just cyclical," she argued. "It's structural."
A major factor is demographics. 
As the Baby Boomer generation retires, Alden noted that Social Security's $3 trillion trust fund will be spent down, injecting more money into the economy while limiting political appetite for fiscal restraint. 
Also Read: <a href="https://www.benzinga.com/cannabis/25/05/45698521/bitcoin-drops-to-105000-after-trump-warns-hes-no-longer-mr-nice-guy">Bitcoin Drops To $105,000 After Trump Warns He&#8217;s &#8216;No Longer Mr. Nice Guy&#8217;</a>
"It's the third rail of U.S. politics," she said. "No party will touch it."
The result: long-term, unavoidable deficits that persist regardless of the business cycle or who wins elections.
Alden likened the system to a "shark that must keep swimming." 
Citing data from 110 years of debt history, she showed that total debt levels almost never decline. 
"The last time total U.S. debt dropped meaningfully was during the Great Depression and even in 2008, when it fell slightly, the Fed responded by ballooning the monetary base from $1 trillion to $6 trillion."
With U.S. debt now exceeding 100% of GDP and interest rates no longer structurally declining, Alden warned that interest expenses are consuming a rising share of federal outlays. 
"We're in Wonderland," she said. "The tools that worked for decades now operate in reverse."
What&#8217;s Next: In contrast to fiat's "flexible ledger," Alden positioned Bitcoin as a fundamentally different system: one based on absolute scarcity, transparency, and a fixed supply.
"The fiat system always falls back on printing more units," she said. "Bitcoin doesn't allow that."
Her conclusion: The only rational hedge against this unsustainable trajectory is to hold "the highest quality scarce assets, "chief among them, Bitcoin.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/05/45697994/robinhood-ceo-says-political-infighting-is-a-concern-for-crypto-legislation">Robinhood CEO Says Political Infighting Is &#8216;A Concern&#8217; For Crypto Legislation</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

'Nothing Stops This Train': US Fiscal Deficits Drive Bitcoin's Case As A Hedge, Says Lyn Alden

Truist Securities analyst Matthew Coad initiates coverage on Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Sell rating and announces Price Target of $31.

Price Target

Initiation

Analyst Ratings

GLBE

Truist Securities Initiates Coverage On Global E Online with Sell Rating, Announces Price Target of $31

The Campbell's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) affirms FY2025 Adj EPS guidance from $2.95-$3.05 to $2.95-$3.05 vs $2.98 analyst estimate..

Guidance

The Campbell's Affirms FY2025 Adj EPS Guidance of $2.95-$3.05 vs $2.98 Est

Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) ("Rivian") today announced that Rivian Holdings, LLC (the "Company"), Rivian, LLC ("Rivian LLC") and Rivian Automotive, LLC ("Rivian Automotive" and, together with the Company and Rivian LLC, the "Co-Issuers") intend to offer, subject to market and other customary conditions, $1,250,000,000 aggregate principal amount of senior secured green notes due 2031 (the "notes") in a private offering. Rivian expects to use the net proceeds from the offering of the notes, together with cash on hand, to redeem in full the $1,250,000,000 aggregate principal amount of the Co-Issuers' outstanding floating rate senior secured notes due 2026 (the "2026 Notes") and pay related fees and expenses. This press release does not constitute a notice of redemption with respect to the 2026 Notes.
The notes are expected to be guaranteed by each of the Company's subsidiaries that also guarantee the Co-Issuers' senior secured asset-based revolving credit facility (the "ABL Facility"). The notes and the guarantees are expected to be secured on a first-priority basis by substantially all assets of the Co-Issuers and the guarantors, other than ABL Priority Collateral (as defined below), if and when the previously announced loan facility with the Department of Energy is funded, on a first-priority basis by substantially all assets of Rivian New Horizon, LLC, and on a second-priority basis by the inventory, receivables, certain deposit accounts and certain related assets (which exclude intellectual property) which secure the ABL Facility on a first-priority basis (the "ABL Priority Collateral"), in each case subject to certain excluded assets and permitted liens.

RIVN

Rivian Automotive Intends To Offer $1.25B Senior Secured Green Notes Offering To Refinance Outstanding Senior Secured Notes due 2026

Campbell Soup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NYSE">CPB</a>) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of $0.66 by 10.61 percent. This is a 2.67 percent decrease over earnings of $0.75 per share from the same period last year. The company reported quarterly sales of $2.48 billion which beat the analyst consensus estimate of $2.43 billion by 1.83 percent. This is a 4.47 percent increase over sales of $2.37 billion the same period last year.

Earnings

Earnings Beats

Campbell Soup Q3 Adj. EPS $0.73 Beats $0.66 Estimate, Sales $2.48B Beat $2.43B Estimate

Truist Securities analyst Matthew Coad initiates coverage on Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Sell rating and announces Price Target of $60.

Truist Securities Initiates Coverage On Block with Sell Rating, Announces Price Target of $60

TradePulse Alert Confirms Early Up Move in LLY
<figure class="wp-block-image size-large"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/30203153/Screenshot-2025-05-30-at-4.23.48%E2%80%AFPM-992x1024.png" alt="" class="wp-image-13683" /></figure>
Eli Lilly (LLY) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:24 AM on May 30th, a significant trading signal occurred for Eli Lilly (LLY) as it demonstrated a Power Inflow at a price of $734.98. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Lilly's stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Lilly's stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock's overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for LLY, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like <a href="https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025">https://tradepulse.net/?utm_source=Benzinga&amp;utm_medium=Article&amp;utm_campaign=brand_awareness_May2025</a> which are responsible for parts of the data within this article.
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved
After Market Close UPDATE:
The price at the time of the Power Inflow was $734.98. The returns on the High price ($745.93) and Close price ($737.87) after the Power Inflow are respectively 1.5% and 0.4%. The result underlines the importance of a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite.
Results are not indicative of future results

Equities

WIIM

Technicals

Opinion

Signals

Eli Lilly Rises 1.5% After Key Trading Signal

Nokia and Andorix partner to accelerate Private 5G and Edge solutions in North American real estate market&nbsp;
<ul>
<li>Private 5G, Neutral Host Network and Edge Application OT solutions enabled by Nokia Digital Automation Cloud (DAC) to enable efficient building operations and improve tenant's satisfaction.&nbsp; &nbsp;</li>
</ul>

Nokia Teams Up With Andorix To Expand Indoor 5G and Edge Solutions Across U.S. And Canadian Properties

~ Alignment with FDA continues to support Accelerated Approval pathway ~
~ BLA submission planned for first quarter of 2026 ~
~ Conference call today at 8:30 a.m. ET ~
LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=KJrUuvgpMd-Ddja3YfjTaW-sEFYSuEc8TNCL8DhDuaFHTkrvl5gSZYYVlr1J5ubOEYW0Znoht2JKxs4d8ldSNg==">uniQure</a> N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington's disease. Following recent Type B meetings and further guidance from the U.S. Food and Drug Administration (FDA), the Company has reached alignment with the FDA on several key components of the statistical analysis plan and Chemistry, Manufacturing and Controls (CMC) information that will support a Biologics License Application (BLA) submission expected in the first quarter of 2026.
Statistical Analysis Plan
In the second quarter of 2025, the Company held a Type B meeting with the FDA to discuss the proposed use of external control data and the prospectively defined statistical analysis plan (SAP) in support of the planned BLA submission for AMT-130. The FDA continued to support its prior agreement that the composite Unified Huntington's Disease Rating Scale (cUHDRS) may serve as an acceptable registrational, intermediate clinical endpoint for accelerated approval. The FDA agreed that the primary efficacy analysis for the BLA will evaluate the 3-year change in cUHDRS in high-dose AMT-130 patients compared to a propensity score-adjusted external control arm. The Company plans to use propensity score-weighted external control derived from the ENROLL-HD dataset for the primary analysis and to submit certain sensitivity analyses, including one using a propensity score-matched external control, as additional support.
The FDA also agreed that ENROLL-HD – a large, prospective, longitudinal, natural history study of patients with Huntington's disease – may be acceptable as the external control dataset for the primary analysis of the trial data along with additional sensitivity analyses using the TRACK-HD/TRACK-ON and PREDICT-HD datasets. To date, approximately 33,000 patients have enrolled in ENROLL-HD. Compared to previously used natural history studies like TRACK-HD and PREDICT-HD, ENROLL-HD offers a substantially larger sample size, lower attrition rates, and longer average patient follow-up. The Company expects the larger sample size to reduce variability in the external control data and enhance the robustness of the SAP.
The Company plans to submit an updated SAP consistent with discussions from the recently held Type B meeting to the FDA in the second quarter of 2025.
Chemistry, Manufacturing and Controls (CMC)
In the first quarter of 2025, the Company held a Type B meeting with the FDA to discuss CMC requirements in support of the planned BLA submission for AMT-130. The FDA agreed that validation of the AMT-130 manufacturing process should be possible using experience and prior knowledge from the etranacogene dezaparvovec-drlb (HEMGENIX&#xAE;) process, complemented with additional full-scale AMT-130 GMP batches and a single Process Performance Qualification (PPQ) batch.
The FDA also agreed with the Company's proposed drug product release testing plan, including the proposed potency assay, pending completion of qualification and specification setting activities.
Next Steps for the Planned BLA Submission
Based on these recent Type B meetings with the FDA, the Company continues to prepare for a BLA submission for AMT-130 in the treatment of Huntington's disease. Certain key next steps and expected timing include:
<ul>
<li>Q2 2025: submit updated SAP to the FDA &nbsp;</li>
<li>Q3 2025: initiate PPQ run and present topline Phase I/II data per the SAP &nbsp;</li>
<li>Q4 2025: hold pre-BLA meeting with the FDA &nbsp;</li>
<li>Q1 2026: submit BLA with a request for priority review designation &nbsp;</li>
</ul>

QURE

uniQure Secures FDA Alignment On AMT-130, Targeting 2026 BLA Submission

Asset Sales

Dow Announced That It Has Signed A Sale And Purchase Agreement To Sell Its 50% Interest In Dowaksa Advanced Composites Holdings Bv (Dowaksa) To Aksa Akrilik Kimya Sanayii A.Ş For Proceeds Of $125M

NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), often dubbed China&#8217;s Tesla, announced its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/g45711427/nio-inc-provides-may-2025-delivery-update" rel="noreferrer noopener">May 2025 delivery results</a> on Monday.
NIO delivered 23,231 vehicles in May 2025, an increase of 13.1% year-over-year. The company&#8217;s newer brands, ONVO and FIREFLY, played a significant role in this growth.
The deliveries comprised 13,270 vehicles from the company&#8217;s premium smart electric vehicle brand NIO, 6,281 vehicles from the company&#8217;s family-oriented smart electric vehicle brand ONVO, and 3,680 vehicles from the company&#8217;s small smart high-end electric car brand FIREFLY.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/asia/25/05/45692725/alibaba-and-baidu-turn-to-chinese-ai-chips-as-us-sanctions-squeeze-nvidia-supply" rel="noreferrer noopener">Alibaba And Baidu Turn To Chinese AI Chips As US Sanctions Squeeze Nvidia Supply</a>
Year-to-date, NIO has delivered a total of 89,225 vehicles in 2025, marking a 34.7% increase year-over-year, the company said in a press release.
As of May 31, 2025, cumulative deliveries for the company have reached 760,789 vehicles.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) experienced a <a target="_blank" href="https://www.benzinga.com/news/topics/25/06/45716179/teslas-china-sales-slump-while-byd-and-li-auto-post-strong-gains-report" rel="noreferrer noopener">decline in sales</a> in China compared to rivals like&nbsp;NIO, Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>),&nbsp;Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), and&nbsp;BYD Co., which posted strong growth in May.
NIO stock is down over 22% and 34% in the last 12 months. It grappled with&nbsp;challenges in achieving full-year profitability, primarily due to high research and development expenses and significant operational costs.
Trump administration&#8217;s tariff policies posed additional headwinds.
On May 12, Beijing and Washington <a href="https://www.benzinga.com/government/regulations/25/05/45676270/chinese-stocks-soar-as-us-court-blocks-trump-tariffs" target="_blank" rel="noreferrer noopener">agreed to lower tariffs</a> on each other&#8217;s products, temporarily offering relief to the stock market. The deal reduced U.S. levies of 145% on most Chinese imports to 30%, while China&#8217;s 125% duties on U.S. goods will drop to 10% for 90 days.
Price Actions: NIO stock is trading higher by 1.98% to $3.61 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45679204/apple-iphone-shipment-could-decline-in-2025-as-tariff-competition-play-spoil-sport-idc" target="_blank" rel="noreferrer noopener">Apple iPhone Shipment Could Decline In 2025 As Tariff, Competition Play Spoil Sport: IDC</a></li>
</ul>
Photo by Tada Images via Shutterstock

Asia

Movers

Tech

TSLA

XPEV

China's NIO Clocks 13% Deliveries Growth In May, Tesla Lags

Pharmacokinetics (PK)
KT-621 demonstrated a favorable plasma PK profile after single and multiple doses. Rapid absorption was demonstrated with a median tmax of 2-4 hours and a mean half-life of 9-36 hours. There was a dose-proportional increase in exposure after multi-dosing and steady-state was achieved by Day 4.
Pharmacodynamics (PD)
KT-621 demonstrated rapid, deep and prolonged STAT6 degradation in blood after single doses of KT-621 and in blood and skin after multiple doses of KT-621.
STAT6 levels in blood and skin were measured using a highly sensitive and quantitative mass spectrometry assay. Complete degradation within a cohort is defined as either a mean reduction of ≥95% or when most subjects' STAT6 levels are reduced below the Lower Limit of Quantification (LLOQ), or both.
In SAD, maximal degradation was achieved in blood as quickly as the first collected timepoint of 4 hours after a single dose, with mean STAT6 degradation reaching &gt;90% across all SAD doses starting at 6.25 mg. All SAD cohorts at doses of 75 mg or greater achieved &gt;95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects.
In MAD, robust STAT6 degradation was observed in blood at the first timepoint measured (8 hours) for doses above 1.5 mg. Steady-state, complete degradation, associated with STAT6 reductions below the LLOQ in the majority of subjects, was achieved at doses ≥50 mg with recovery starting as early as 4 days post-last dose.
In MAD, robust STAT6 degradation was observed in skin at the first timepoint measured (Day 7) for doses above 1.5 mg. Steady-state, complete degradation, associated with ≥95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects, was achieved at doses ≥50 mg.
Th2 Biomarkers
The impact of STAT6 degradation on Th2 biomarkers was assessed in the MAD cohorts, despite the low baseline levels typically seen in healthy volunteers. TARC reduction was observed for all KT-621 dose groups, with median reduction of up to 37% at Day 14. We believe these results are comparable or superior to what was seen in the dupilumab healthy volunteer study. In line with the dupilumab study in healthy volunteers, minimal IgE reductions were observed given the low levels of IgE at baseline and the short duration of treatment. Eotaxin-3, a highly specific downstream cytokine of the IL-4/IL-13 pathway, was also measured. Eotaxin-3 reduction was observed for all KT-621 dose groups with a median reduction of 63% at Day 14. These results are superior to what has been reported with dupilumab in asthma or chronic rhinosinusitis with nasal polyps (CRSwNP) patients even at 52 weeks.
Safety and Tolerability
The safety profile of KT-621 was undifferentiated from placebo. There were no serious adverse events (SAEs), no severe AEs, no treatment related adverse events (TRAEs) in more than one subject, no TRAEs leading to discontinuation, and no clinically relevant changes in vital signs, laboratory tests and ECGs.
Next Steps
The Company's KT-621 BroADen Phase 1b trial in moderate to severe AD patients is ongoing, with data expected to be reported in the fourth quarter of 2025. Two parallel Phase 2b trials in AD and asthma are planned to start in 4Q25 and 1Q26, respectively. These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Th2 dermatology, gastroenterology and respiratory indications.

Biotech

Health Care

General

KYMR

Kymera Therapeutics Announced Clinical Results From The Phase 1 Healthy Volunteer Study Of KT-621

BCRX

BioCryst To Present New ORLADEYO Data At 2025 EAACI Meeting, Highlighting HAE Prophylaxis In Adults and Children

AngloGold Ashanti plc ("AngloGold Ashanti", "AGA" or the "Company") has agreed to sell its interest in Mineração Serra Grande mine ("MSG") located in the state of Goiás, Brazil, to Aura Minerals Inc. ("Aura").
The Company will sell Mineração Serra Grande S.A. ("Sale"), which owns MSG to a Brazilian incorporated affiliate of Aura ("Purchaser") for the following consideration:
<ul>
<li>A cash consideration of $76 million on closing subject to certain working capital adjustments as at the closing date; and</li>
<li>Deferred Consideration Payments equivalent to a 3% net smelter returns participation over the current Mineral Resource of MSG inclusive of the Mineral Reserve – these Deferred Consideration Payments will be paid quarterly in cash.</li>
</ul>
The recent focus at MSG has been on stabilizing the operations including the decommissioning of the legacy tailings storage facility ("TSF Decharacterization") which is nearing completion. However, MSG remains one of AGA's higher cost and its smallest operation by production.
"This sale ensures we further sharpen our focus on capital allocation, operating efficiencies and the optimization of our portfolio," said AngloGold Ashanti CEO Alberto Calderon. "We've also worked hard to ensure that MSG and its excellent team joins an established company which will continue to be responsible stewards of this asset for the benefit of all stakeholders."
The Sale excludes certain subsidiaries of Mineração Serra Grande S.A which hold assets that do not form part of MSG's mining operations and include properties. These will remain in the AGA group and will be transferred from under Mineração Serra Grande S.A. by means of a spin-off prior to closing ("MSG Subsidiaries Transfer").
The Disposal is subject to the fulfilment of the following conditions:
i. Anti-trust approval from the Brazilian authorities (CADE); ii. The completion of the TSF Decharacterization work; iii. The completion of the MSG Subsidiaries Transfer; and iv. No Material Adverse Event occurring prior to closing.
It is expected that all the conditions will be fulfilled, and the Sale is expected to close during Q3 2025.

AngloGold Sells Brazil Mine to Aura Minerals for $76M, Plus Future Royalties

NBIS

Nebius Invests In ClickHouse Series C To Unlock Value And Fuel AI Infrastructure Expansion

JBIO

Jade Biosciences Announced New Preclinical Data On JADE101, Its Anti-april Monoclonal Antibody Being Developed For The Treatment Of IgA Nephropathy (IgAN)

A. New proteoElute nanoflow nLC system features ceramic valves, proteoTrap trapping columns, and TwinScape-enabled predictive maintenance technology
B. Introducing new generation of PepSep Advanced nLC columns to further improve chromatographic resolution, sensitivity and proteomics identifications
At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com%2F&amp;esheet=54263257&amp;newsitemid=20250602715993&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=17d2f94ec69b3f1e87b36b18a38df92a">Bruker Corporation</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced the new proteoElute nanoLC system, featuring ceramic valves, proteoTrap trapping columns, and next-generation PepSep Advanced nLC columns, further enhancing robustness, sensitivity and proteome coverage in ultra-sensitive proteomics workflows.

BRKR

Bruker Launches proteoElute nanoLC System, Advancing Ultra-Sensitive Proteomics

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439734-1&amp;h=3498642422&amp;u=https%3A%2F%2Fwww.trevitherapeutics.com%2F&amp;a=Trevi+Therapeutics%2C+Inc.">Trevi Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio&#x2122; (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), is pleased to announce today positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF (N=165). The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups at Week 6. The 108 mg BID, 54 mg BID and 27 mg BID dose groups achieved reductions from Baseline of 60.2% (p&lt;0.0001), 53.4% (p&lt;0.0001), and 47.9% (p&lt;0.01), respectively, compared to a placebo reduction from Baseline of 16.9%1.&nbsp;Statistically significant improvements were observed across&nbsp;secondary endpoints at Week 6 in the 108 mg BID and 54 mg BID dose groups.

TRVI

Trevi's Cough Drug Haduvio Shows Results in IPF Patients, Cutting Coughs by Over 60%

SCIEX And Evosep Sign Reseller Agreement To Expand Access To Standardized High-Throughput Proteomics For Pharma And Biotech

ZLAB

Zai Lab Limited Announced That Updated Data From An Ongoing, Global Phase 1A/1B Clinical Trial (NCT06179069) Evaluating Zocilurtatug Pelitecan, Or Zl-1310, The Company's Potential First-in-class, Delta-like Ligand (DLL3) Antibody-drug Conjugate (ADC) For Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Press Releases

Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue

Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025

Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results

Standard BioTools to Participate in Upcoming Investor Conferences

Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025

Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025

Standard BioTools Reports First Quarter 2025 Financial Results

Standard BioTools to Host Inaugural "Proteomics Roundtable" Webcast Series

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Atlantic International Corp. - Common Stock

Atlantic International

Azenta

BioLife Solutions

Bruker

Codexis

Cytek Biosciences

CryoPort

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Standard BioTools

ニュース

パートナーシップ

ベンジンガ・グローバル